Salvage therapy with an Albuvirtide-based antiretroviral regimen for multi-drug resistant HIV and drug-resistant HBV with renal impairment: a case report. [PDF]
He Y, Liao B, Liu Y, Cao Y, Li L, Cai W.
europepmc +1 more source
Pharmacological advances in HIV treatment: from ART to long-acting injectable therapies. [PDF]
Łupina K+6 more
europepmc +1 more source
Statistical modelling and forecasting of HIV and anti-retroviral therapy cases by time-series and machine learning models. [PDF]
Almarashi AM.
europepmc +1 more source
Coxiella burnetii and HIV infection in people experiencing homelessness. [PDF]
de França DA+4 more
europepmc +1 more source
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. [PDF]
Geretti AM+15 more
europepmc +1 more source
Antiretroviral medications for pediatric use in the context of the Unified Health System: are there therapeutic gaps in Brazil? [PDF]
Costa SMD, Aguiar PM.
europepmc +1 more source
Related searches:
Pyrazole Containing Anti-HIV Agents: An Update
Medicinal Chemistry, 2022Background:Pyrazole scaffolds have gained importance in drug discovery and development for various pharmacological activities like antiviral, antifungal, anticancer, antidepressant, antiinflammatory, antibacterial, etc. Additionally, the pyrazole moiety has shown potent anti-HIV activity as a core heterocycle or substituted heterocycles derivatives ...
Sanjay, Kumar+3 more
openaire +3 more sources
Naturally derived anti‐HIV agents
Phytotherapy Research, 2005AbstractThe urgent need for new anti‐HIV/AIDS drugs is a global concern. In addition to obvious economical and commercial hurdles, HIV/AIDS patients are faced with multifarious difficulties associated with the currently approved anti‐HIV drugs. Adverse effects, the emergence of drug resistance and the narrow spectrum of activity have limited the ...
Asres, Kaleab+4 more
openaire +5 more sources
New anti‐HIV agents and targets
Medicinal Research Reviews, 2002AbstractVirtually all the compounds that are currently used or are subject of advanced clinical trials for the treatment of HIV infections, belong to one of the following classes: (i) nucleoside reverse transcriptase inhibitors (NRTIs): i.e., zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, emtricitabine and nucleotide reverse ...
E. Clercq
openaire +5 more sources